ReviewCurrent genetics2016
Pseudomonas aeruginosa: breaking down barriers.
Review in Current genetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Genomic diversity ofMicrobial genomics · 2026Article
- A Pseudomonas aeruginosa quorum-sensing inducer controls lung permeability in establishing chronic infection via EGFR.Nature communications · 2025Article
- Exploiting Salmonella typhimurium as a novel cancer therapeutic agent: from tumor colonization to metabolic engineering.World journal of microbiology & biotechnology · 2025Review
- Advances in Plant-Derived Extracellular Vesicle Extraction Methods and Pharmacological Effects.Biology · 2025Review
- The promoting role of aluminum oxide nanoparticles in enhancingOpen veterinary journal · 2025Article
- Pseudomonas aeruginosa elongation factor-Tu (EF-Tu) is an immunogenic protective protein antigen.Vaccine · 2024Article
- Lung endothelium, tau, and amyloids in health and disease.Physiological reviews · 2024Review
- Determination of Ideal Factors for Early Adoption and Standardization of Metagenomic Next-generation Sequencing for Respiratory System Infections.Current pharmaceutical biotechnology · 2024Article
- Fine Particulate Matter Perturbs the Pulmonary Microbiota in Broiler Chickens.Animals : an open access journal from MDPI · 2023Article
- Pseudomonas aeruginosa pulmonary infection results in S100A8/A9-dependent cardiac dysfunction.PLoS pathogens · 2023Article
- Isolation and Characterization of Three Pseudomonas aeruginosa Viruses with Therapeutic Potential.Microbiology spectrum · 2023Article
- Bacterial-fungal interactions and their impact on microbial pathogenesis.Molecular ecology · 2023Review
- Article
- Treatment with paeoniflorin increases lifespan ofFrontiers in pharmacology · 2023Article
- Immunopathology of Renal Tissue in Fatal Cases of Dengue in Children.Pathogens (Basel, Switzerland) · 2022Article
- Article
- C3aR plays both sides in regulating resistance to bacterial infections.PLoS pathogens · 2022Review
- Antibiotic-resistant organisms establish reservoirs in new hospital built environments and are related to patient blood infection isolates.Communications medicine · 2022Article
- The Threat of Carbapenem-Resistant Gram-Negative Bacteria in Patients with Hematological Malignancies: Unignorable Respiratory Non-Fermentative Bacteria-Derived Bloodstream Infections.Infection and drug resistance · 2022Article
- Beneficial effect of Xuebijing againstFrontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Many bacterial pathogens have evolved ingenious ways to escape from the lung during pneumonia to cause bacteremia. Unfortunately, the clinical consequences of this spread to the bloodstream are frequently dire. It is therefore important to understand the molecular mechanisms used by pathogens to breach the lung barrier. We have recently shown that Pseudomonas aeruginosa, one of the leading causes of hospital-acquired pneumonia, utilizes the type III secretion system effector ExoS to intoxicate pulmonary epithelial cells. Injection of these cells leads to localized disruption of the pulmonary-vascular barrier and dissemination of P. aeruginosa to the bloodstream. We put these data in the context of previous studies to provide a holistic model of P. aeruginosa dissemination from the lung. Finally, we compare P. aeruginosa dissemination to that of other bacteria to highlight the complexity of bacterial pneumonia. Although respiratory pathogens use distinct and intricate strategies to escape from the lungs, a thorough understanding of these processes can lay the foundation for new therapeutic approaches for bacterial pneumonia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.